Fulcrum Therapeutics, Inc.'s pociredir shows promise in treating Sickle Cell Disease, with key data from 12 mg and 20 mg cohorts expected in mid and late 2025 respectively. Despite a setback with ...

Risto-cel, a gene-edited cell therapy formerly called BEAM-101, for severe SCD, benefits patients for nearly two years, new ...

Patients with sickle cell disease (SCD) who wore an Apple Watch and reported daily pain scores could have their pain scores accurately predicted during hospital admission for vaso-occlusive crises and ...

A cross-sectional analysis assessed the birth prevalence of sickle cell disease (SCD) alongside data on social vulnerability to highlight the needs of communities impacted by SCD. SCD, a blood ...

Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease treatment; Data expected in 2024. The company has chosen to cut out several programs ...

Editas Medicine EDIT announced positive preliminary safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY study and the first ...